vimarsana.com
Home
Live Updates
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update : vimarsana.com
Celcuity Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Granted Breakthrough Therapy designation by the FDA for gedatolisib in HR+/HER2- advanced breast cancerEntered into agreements for the private placement sale of $100 million of equity and to increase available
Related Keywords
United States ,
Vicky Hahne ,
Kostenloser Wertpapierhandel ,
Robert Uhl ,
Brian Sullivan ,
Exchange Commission On ,
Drug Administration ,
Nasdaq ,
Innovatus Life Sciences Strategy ,
Enterprise Associates ,
Armentum Partners ,
Celcuity Inc ,
European Medicines Agency ,
Innovatus Capital Partners ,
Granted Breakthrough Therapy ,
Breakthrough Therapy Designation ,
Venrock Healthcare Capital Partners ,
Commodore Capital ,
New Enterprise Associates ,
Soleus Capital ,
Chief Executive ,
Breakthrough Therapy ,
Fast Track ,
Conference Call ,
Capital Partners ,
Risk Factors ,
Quarterly Report ,
Exchange Commission ,
Stockholder Equity ,
Months Ended June ,
Net Loss ,
Loss Per Share ,
Net Loss Per ,
Celcuity ,
Reports ,
Second ,
Quarter ,
022 ,
Financial ,
Results ,
Rovides ,
Corporate ,
Update ,
vimarsana.com © 2020. All Rights Reserved.